BioLineRx (BLRX) Operating Expenses (2013 - 2025)
BioLineRx (BLRX) posted Operating Expenses of -$3.5 million for Q4 2025, down 38.82% on a QoQ basis from -$2.6 million in Q3 2025, and up 6.37% year-over-year from -$3.3 million in Q4 2024.
BioLineRx (BLRX) has 13 years of Operating Expenses data on file, last reported at -$3.5 million in Q4 2025.
- In Q4 2025, Operating Expenses rose 6.37% year-over-year to -$3.5 million; the TTM figure through Dec 2025 stood at -$11.2 million (up 27.36% YoY), while the FY2025 annual figure was -$11.2 million, up 27.36% from the prior year.
- Operating Expenses slipped to -$3.5 million in Q4 2025, from -$2.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $4.3 million in Q2 2022 and bottomed at -$6.3 million in Q4 2021.
- A 5-year average of -$3.5 million and a median of -$4.1 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses tumbled 199.19% — and 2025, when it surged 35.52%.
- Year by year, Operating Expenses stood at -$6.3 million in 2021, then climbed by 20.2% to -$5.0 million in 2022, then slipped by 5.19% to -$5.3 million in 2023, then increased by 28.79% to -$3.8 million in 2024, then climbed by 6.37% to -$3.5 million in 2025.
- The last three Operating Expenses figures came in at -$3.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$2.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 898.54 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.54 Mn |
| Sep 30, 2025 | -2.55 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Mar 31, 2025 | -2.61 Mn |
| Dec 31, 2024 | -3.78 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -3.85 Mn |
| Mar 31, 2024 | -3.88 Mn |
| Dec 31, 2023 | -5.31 Mn |
| Sep 30, 2023 | -4.23 Mn |
| Jun 30, 2023 | -4.31 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -5.05 Mn |
| Sep 30, 2022 | -5.76 Mn |
| Jun 30, 2022 | 4.35 Mn |
| Mar 31, 2022 | -5.44 Mn |
| Dec 31, 2021 | -6.33 Mn |
| Sep 30, 2021 | -5.97 Mn |
| Jun 30, 2021 | 4.10 Mn |
| Mar 31, 2021 | -5.30 Mn |
| Dec 31, 2020 | -5.70 Mn |
| Sep 30, 2020 | -4.34 Mn |
| Jun 30, 2020 | 3.90 Mn |
| Mar 31, 2020 | -6.67 Mn |
| Dec 31, 2019 | -9.24 Mn |
| Sep 30, 2019 | -6.44 Mn |
| Jun 30, 2019 | 4.35 Mn |
| Mar 31, 2019 | -5.32 Mn |
| Dec 31, 2018 | -6.81 Mn |
| Sep 30, 2018 | -5.92 Mn |
| Jun 30, 2018 | 3.60 Mn |
| Mar 31, 2018 | -6.15 Mn |
| Dec 31, 2017 | -7.21 Mn |
| Sep 30, 2017 | -6.81 Mn |
| Jun 30, 2017 | 3.22 Mn |
| Mar 31, 2017 | -4.62 Mn |
| Dec 31, 2016 | -3.96 Mn |
| Sep 30, 2016 | -4.08 Mn |
| Jun 30, 2016 | -3.59 Mn |
| Mar 31, 2016 | -3.53 Mn |
| Dec 31, 2015 | -3.92 Mn |
| Sep 30, 2015 | -3.34 Mn |
| Jun 30, 2015 | -3.87 Mn |
| Mar 31, 2015 | -4.07 Mn |
| Dec 31, 2014 | -4.57 Mn |
| Sep 30, 2014 | -3.77 Mn |
| Jun 30, 2014 | -3.63 Mn |
| Mar 31, 2014 | -3.71 Mn |
| Dec 31, 2013 | -1.88 Mn |
| Sep 30, 2013 | -3.07 Mn |
| Jun 30, 2013 | -4.34 Mn |
| Mar 31, 2013 | -6.30 Mn |